Brain Scientific announces CE Mark for the NeuroCap™ device


Brain Scientific Inc.

LAKEWOOD RANCH, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) — via InvestorWire — –– brain science (OTCQB: BRSF), a Florida-based medical device company, today announced that it has received the Conformité Européenne (CE) Mark for NeuroCap™. The CE Mark confirms that Brain Scientific has met all the requirements of the European Medical Devices Directive to begin marketing its innovative neurological devices across the European continent and other CE marked regions.

“The CE Mark is another certification that demonstrates the effectiveness of Brain Scientific’s technologies,” said Daniel Cloutier, CEO of LOK Corporation. “We have seen strong demand for NeuroCap™ from European neurologists and distributors, and now with the CE Mark, Brain Scientific can begin selling to medical institutions in Europe.”

“Our neurological products are accelerating access to EEG testing both in hospitals and in the field,” said Hassan Kotob, Chairman and CEO of Brain Scientific. “The CE mark is a crucial step forward as we increase our market penetration in Europe.”

Brain Scientific has developed two different devices to streamline EEG preparation, testing and diagnosis. NeuroCap™ features 22 pre-gelled electrodes, making it a suitable option for most clinical EEG testing, including routine EEGs commonly used in stroke and epilepsy patients. Fixed electrode placement conforms to the international 10-20 system. NeuroEEG™ is a 21-channel amplifier that offers doctors the same quality as conventional EEG machines.

The NeuroCap™ is an FDA 510k cleared, pre-gelled, disposable EEG headset for clinical use. With the NeuroCap™, any clinician can prepare a patient for an EEG scan in a fraction of the time it normally takes to apply individual electrodes. The NeuroCap™ can be used in almost any setting including rural hospitals, ambulances, private practices and sporting events, greatly expanding access to EEG testing. It is currently available in four sizes, including pediatric sizes.

About Brain Scientific

brain science ( is a multi-patent medical device company with FDA-cleared products. Brain Scientific is committed to developing next-generation solutions that drive the future of neurodiagnostic and medical OEM devices. Brain Scientific has two product lines covering Neurology and Precision Movement. NeuroCap™ and NeuroEEG™ are intelligent neurological diagnostic devices that simplify administration, reduce scan time and reduce costs. The Piezo Motion product line consists of highly efficient, compact, precision motors that will power the next generation of medical devices. To learn more about Brain Scientific’s corporate strategy, products or investor relations, please visit

Forward-Looking Statements

All statements contained in this press release that are not historical facts may constitute forward-looking statements. Forward-looking statements may include, without limitation, statements regarding (i) management’s plans and objectives for future operations, including plans or objectives relating to the design, development and commercialization of EEG products and services and piezo motor technology; (ii) a projection of earnings (including earnings/losses), earnings (including earnings/losses) per share, capital expenditures, dividends, capital structure or other financial item; (iii) the future financial performance of the company; (iv) the successful integration of Piezo Motion with and into Brain Scientific; and (v) the assumptions underlying or relating to any statement described in items (i), (ii), (iii) or (iv) above. Such forward-looking statements are not intended to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based on the Company’s current forecasts, plans, goals, beliefs, expectations, estimates and assumptions and these is subject to a number of risks and uncertainties and other influences, many of which are beyond the Company’s control. Actual results and the timing of certain events and circumstances could differ materially from those described in the forward-looking statements due to these risks and uncertainties. Factors that may affect or contribute to the inaccuracy of the forward-looking statements, or cause actual results to differ materially from those anticipated or desired, include, among others, the Company’s inability to obtain additional financing; the significant time and resources involved in developing products and the associated inadequate cash flows and resulting illiquidity; the Company’s inability to expand its business; significant government regulation of medical devices and the healthcare industry; lack of product diversification; volatility in the price of the Company’s raw materials; and failure to implement the company’s business plans or strategies. Some of these and other factors are identified and described in more detail in the Company’s filings with the SEC. The company undertakes no obligation to update these forward-looking statements.


[email protected]

[email protected]

corporate communications

IBN (Investor Brand Network)
Los Angeles, California
310.299.1717 office
[email protected]


Comments are closed.